<DOC>
	<DOCNO>NCT01872299</DOCNO>
	<brief_summary>SICA-HF prospective , multicentre , multinational , longitudinal , pathophysiological evaluation study , conduct 11 centre across six country . SICA-HF receives fund European commission 's Seventh Framework Programme ( FP7/2007-2013 ) grant agreement . 241558 ( SICA-HF ) Russian Ministry Science Education within file transfer protocol `` R &amp; D priority field S &amp; T complex Russia 2007-2012 '' state contract number 02.527.11.0007 . The aim SICA-HF provide detail characteristic co-morbidities heart failure baseline time , particularly regard obesity , cachexia , type 2 diabetes .</brief_summary>
	<brief_title>Studies Investigating Co-morbidities Aggravating Heart Failure</brief_title>
	<detailed_description>SICA-HF , consist outstanding European heart failure clinicians basic researcher , accomplish provide common platform two different research team . All partner SICA-HF recruit 1462 patient chronic heart failure , 199 patient type 2 diabetes without heart failure , 173 healthy control subject . Thus , last year , cumulative 91.4 % target value achieve patient chronic heart failure , 66.3 % target value diabetic control , 115.3 % thus over-achieving healthy subject . The data participating center collect entered central database . As writing , 1469 chronic heart failure patient ' visit , 255 diabetic control ' visit , 167 healthy control ' visit enter online database . In total , 171 patient report decease ; total number hospitalization 2232 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : Clinical diagnosis heart failure ; Objective evidence cardiac dysfunction evidence least ONE following : left ventricular ejection fraction ≤ 40 % ; left atrial dimension &gt; 4.0 cm ( &gt; 2.5 cm/m height ) NTproBNP &gt; 400 pg/ml [ &gt; 47.3 pmol/l ] ( BNP &gt; 150 pg/ml ) Current treatment loop diuretic ; Age &gt; 18 year ; Willingness provide informed consent Exclusion criterion : Congenital heart disease ; Any lifethreatening disease heart failure ; Active malignancy type , history malignancy within previous 5 year ; Previous heart transplantation ; Intravenous therapy heart failure give within previous 72 hour ; Severe neuromuscular disease ; History unstable angina , myocardial infarction stroke within 3 month prior study ; Pregnancy ; Treatment immunosuppressive therapy , e.g . steroid rheumatoid arthritis obstructive lung disease ; Significant renal dysfunction , define serum creatinine &gt; 250 μmol/L [ &gt; 2.8 mg/dL ] ; Severe liver disease , define liver function test &gt; 3 time upper limit normal ; Unable understand comply protocol give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>